Most Read Articles
Roshini Claire Anthony, 6 days ago

In patients with osteoporosis treated with denosumab, a long interval between injections could raise their risk of vertebral fracture, a UK-based retrospective study showed.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Roshini Claire Anthony, 08 Sep 2020

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.

Product Highlight - Clipax

29 Nov 2019
• First-line chemotherapy of ovarian cancer, CLIPAX is indicated for the treatment of patients with advanced disease or residual disease (>1 cm) after initial laparotomy, in combination with Cisplatin.

• Second line chemotherapy of ovarian cancer, CLIPAX is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy.

• In the adjuvant setting, CLIPAX is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and Cyclophosphamide (AC) therapy.

• CLIPAX in combination with Cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy.



Reference:
Clipax Full Prescribing Information.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

In patients with osteoporosis treated with denosumab, a long interval between injections could raise their risk of vertebral fracture, a UK-based retrospective study showed.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Elaine Soliven, 6 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Roshini Claire Anthony, 08 Sep 2020

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.